569 related articles for article (PubMed ID: 27256364)
81. Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies.
Du X; Parent JM
Curr Neurol Neurosci Rep; 2015 Oct; 15(10):71. PubMed ID: 26319172
[TBL] [Abstract][Full Text] [Related]
82. Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.
Hong SG; Yada RC; Choi K; Carpentier A; Liang TJ; Merling RK; Sweeney CL; Malech HL; Jung M; Corat MAF; AlJanahi AA; Lin Y; Liu H; Tunc I; Wang X; Palisoc M; Pittaluga S; Boehm M; Winkler T; Zou J; Dunbar CE
Mol Ther; 2017 Jan; 25(1):44-53. PubMed ID: 28129126
[TBL] [Abstract][Full Text] [Related]
83. Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges.
Poon A; Zhang Y; Chandrasekaran A; Phanthong P; Schmid B; Nielsen TT; Freude KK
N Biotechnol; 2017 Oct; 39(Pt B):190-198. PubMed ID: 28579476
[TBL] [Abstract][Full Text] [Related]
84. Biliary Atresia Relevant Human Induced Pluripotent Stem Cells Recapitulate Key Disease Features in a Dish.
Tian L; Ye Z; Kafka K; Stewart D; Anders R; Schwarz KB; Jang YY
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):56-63. PubMed ID: 30358741
[TBL] [Abstract][Full Text] [Related]
85. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice.
Wang Y; Zheng CG; Jiang Y; Zhang J; Chen J; Yao C; Zhao Q; Liu S; Chen K; Du J; Yang Z; Gao S
Cell Res; 2012 Apr; 22(4):637-48. PubMed ID: 22310243
[TBL] [Abstract][Full Text] [Related]
86. Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies.
Selvaraj S; Kyba M; Perlingeiro RCR
Trends Mol Med; 2019 Sep; 25(9):803-816. PubMed ID: 31473142
[TBL] [Abstract][Full Text] [Related]
87. Looking into a Crystal Ball: An Interview with Ron Crystal.
Davies K
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):97-101. PubMed ID: 31535944
[No Abstract] [Full Text] [Related]
88. Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases.
Paolini Sguazzi G; Muto V; Tartaglia M; Bertini E; Compagnucci C
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948465
[TBL] [Abstract][Full Text] [Related]
89. A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem Cells.
Kaserman JE; Hurley K; Dodge M; Villacorta-Martin C; Vedaie M; Jean JC; Liberti DC; James MF; Higgins MI; Lee NJ; Washko GR; San Jose Estepar R; Teckman J; Kotton DN; Wilson AA
Stem Cell Reports; 2020 Jul; 15(1):242-255. PubMed ID: 32619491
[TBL] [Abstract][Full Text] [Related]
90. Convergence of human pluripotent stem cell, organoid, and genome editing technologies.
Wang L; Ye Z; Jang YY
Exp Biol Med (Maywood); 2021 Apr; 246(7):861-875. PubMed ID: 33467883
[TBL] [Abstract][Full Text] [Related]
91. Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development.
Donada A; Basso-Valentina F; Arkoun B; Monte-Mor B; Plo I; Raslova H
Stem Cell Res; 2020 Dec; 49():102060. PubMed ID: 33142254
[TBL] [Abstract][Full Text] [Related]
92. Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation.
Paes BCMF; Moço PD; Pereira CG; Porto GS; de Sousa Russo EM; Reis LCJ; Covas DT; Picanço-Castro V
Cell Biol Toxicol; 2017 Jun; 33(3):233-250. PubMed ID: 28039590
[TBL] [Abstract][Full Text] [Related]
93. Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease.
Iwamoto Y; Seki Y; Taya K; Tanaka M; Iriguchi S; Miyake Y; Nakayama EE; Miura T; Shioda T; Akari H; Takaori-Kondo A; Kaneko S
Mol Ther Methods Clin Dev; 2021 Jun; 21():262-273. PubMed ID: 33869654
[TBL] [Abstract][Full Text] [Related]
94. Induced pluripotent stem cells (iPSC)-derived retinal cells in disease modeling and regenerative medicine.
Rathod R; Surendran H; Battu R; Desai J; Pal R
J Chem Neuroanat; 2019 Jan; 95():81-88. PubMed ID: 29448001
[TBL] [Abstract][Full Text] [Related]
95. Progress and prospects: gene therapy clinical trials (part 1).
Alexander BL; Ali RR; Alton EW; Bainbridge JW; Braun S; Cheng SH; Flotte TR; Gaspar HB; Grez M; Griesenbach U; Kaplitt MG; Ott MG; Seger R; Simons M; Thrasher AJ; Thrasher AZ; Ylä-Herttuala S
Gene Ther; 2007 Oct; 14(20):1439-47. PubMed ID: 17909539
[TBL] [Abstract][Full Text] [Related]
96. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
[TBL] [Abstract][Full Text] [Related]
97. New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells.
Garate Z; Davis BR; Quintana-Bustamante O; Segovia JC
Hum Gene Ther; 2013 Jun; 24(6):571-83. PubMed ID: 23675640
[TBL] [Abstract][Full Text] [Related]
98. The safety and effectiveness of genetically corrected iPSCs derived from β-thalassaemia patients in nonmyeloablative β-thalassaemic mice.
Xian Y; Xie Y; Song B; Ou Z; Ouyang S; Xie Y; Yang Y; Xiong Z; Li H; Sun X
Stem Cell Res Ther; 2020 Jul; 11(1):288. PubMed ID: 32678022
[TBL] [Abstract][Full Text] [Related]
99. Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools.
Karwacka M; Olejniczak M
Cells; 2022 Feb; 11(3):. PubMed ID: 35159326
[TBL] [Abstract][Full Text] [Related]
100. Genome-engineering technologies for modeling and treatment of cystic fibrosis.
Dębczyński M; Mojsak D; Minarowski Ł; Maciejewska M; Lisowski P; Mróz RM
Adv Med Sci; 2023 Mar; 68(1):111-120. PubMed ID: 36917892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
